Semantic Scholar uses AI to extract papers important to this topic.
Herein we report that the VEGFR/PDGFR kinase inhibitor sunitinib/SU11248 can accelerate metastatic tumor growth and decrease… Expand Sunitinib (SU011248) is an oral small molecular tyrosine kinase inhibitor that exhibits potent antiangiogenic and antitumor… Expand PURPOSE
Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in… Expand PURPOSE
To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase… Expand Context Sunitinib, a tyrosine kinase inhibitor, has recently been approved for the treatment of gastrointestinal stromal tumors… Expand Cancer chemotherapy has been one of the major medical advances in the last few decades. However, the drugs used for this therapy… Expand PURPOSE
A transgenic mouse model has revealed parameters of the angiogenic switch during multistep tumorigenesis of pancreatic… Expand One challenging aspect in the clinical development of molecularly targeted therapies, which represent a new and promising… Expand FLT3 (fms-related tyrosine kinase/Flk2/Stk-2) is a receptor tyrosine kinase (RTK) primarily expressed on hematopoietic cells. In… Expand The purpose of this study was to evaluate the activity of the indolinone kinase inhibitor SU11248 against the receptor tyrosine… Expand